ETV5: A Protein with Potential as A Drug Target and Biomarker
ETV5: A Protein with Potential as A Drug Target and Biomarker
ETV5, also known as Ets-related protein ERM, is a protein that is expressed in various tissues throughout the body. It is a key regulator of the cell cycle, and its levels have been linked to the development and progression of many diseases, including cancer. In recent years, researchers have been interested in investigating the potential drug targets of ETV5, as well as its potential as a biomarker for certain diseases.
The protein ETV5 is composed of 158 amino acid residues and has a calculated molecular weight of 19.9 kDa. It is expressed in a variety of tissues, including the brain, heart, liver, and pancreas, and is involved in the regulation of cell division and the cell cycle. ETV5 is a critical regulator of the G1/S transition, which is the stage of the cell cycle where the cell prepares for cell division by duplicating its DNA.
In addition to its role in regulating the cell cycle, ETV5 has also been shown to play a role in the development and progression of several diseases. For example, high levels of ETV5 have been linked to the development of pancreatic cancer, and researchers have also found that high levels of ETV5 are associated with an increased risk of certain types of leukemia.
As a potential drug target, ETV5 has been the subject of intense research in recent years. Researchers have been interested in identifying small molecules that can inhibit the activity of ETV5, as this could potentially lead to the development of new treatments for various diseases. One approach that has been used to identify potential drug targets is high-throughput screening (HTS), a technique that involves screening large numbers of small molecules for their ability to interact with a specific protein.
HTS has been used to identify a number of potential drug targets for ETV5, including small molecules that have been shown to inhibit the activity of the protein in cell culture models of cancer. One of the most promising compounds that has been identified is a small molecule called 1-fluoro-2-[(2-methylpropyl)amino]-2-[(2-methylpropyl)amino]-1-propanethiol (SP-4), which is a potent inhibitor of ETV5.
In addition to its potential as a drug target, ETV5 has also been shown to be a potential biomarker for several diseases. For example, researchers have found that ETV5 levels are elevated in the blood of patients with pancreatic cancer, and this increase in ETV5 levels has been associated with poor prognosis. In addition, high levels of ETV5 have also been linked to the development of certain types of leukemia, and these levels have been found to be elevated in the blood of patients with these diseases.
While the potential drug targets of ETV5 and its potential as a biomarker for disease make it an intriguing target for researchers, there are still many questions that need to be answered about its role in the development and progression of disease. For example, it is not yet clear what the full range of ETV5 levels is in the body, or how the levels of ETV5 are regulated in different tissues and diseases. In addition, more research is needed to determine the underlying molecular mechanisms that regulate ETV5 activity and its role in the cell cycle.
Overall, ETV5 is a protein that has significant potential as a drug target and biomarker for the development and progression of disease. While more research is needed to fully understand its role, its properties and its potential as a therapeutic agent make it an important area of study for researchers.
Protein Name: ETS Variant Transcription Factor 5
Functions: Binds to DNA sequences containing the consensus nucleotide core sequence 5'-GGAA.-3'
The "ETV5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ETV5 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ETV6 | ETV7 | Eukaryotic translation initiation factor 2-alpha kinase | Eukaryotic translation initiation factor 2B | Eukaryotic translation initiation factor 3 (eIF-3) complex | Eukaryotic Translation Initiation Factor 4A (eIF-4A) | Eukaryotic Translation Initiation Factor 4E Binding Protein | EVA1A | EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3 | F5 | F7 | F8 | F8A1 | F8A2 | F8A3 | F9 | FA2H | FAAH
